Phase III trials of Novartis' wound-healing agent Apligraf haveshown 80% efficacy in treating diabetic foot ulcers versus 50% using current gold-standard care. Further Phase III data are expected in August, according to Goldman Sachs analysts, with filing due to take place in first-quarter 2000. Peak sales are estimated at $350 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze